Dipankar Bhattacharjee to head Teva's global generics business

Israeli pharma major Teva Pharmaceutical Industries Ltd has appointed Dipankar Bhattacharjee as president and CEO of its global generic medicines group, effective from Monday. Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson, who will step down from his role and remain active with the company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition. Bhattacharjee will be based in the US.

As president and CEO of Teva Generics Europe, Bhattacharjee has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business. Under his leadership, Teva’s European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe. He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches.

Dipankar Bhattacharjee joined the Israeli firm as general manager of Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including vice president commercial in both Europe and Asia-Pacific regions and corporate vice president and president, Asia Pacific Region. He began his career at Nestle SA and Bank of America. Bhattacharjee received his BA degree in economics from St. Stephens College, University of Delhi, and his Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.

“Teva will benefit from Dipankar’s extensive experience in generics and specialty medicines, his financial and operational expertise and his deep understanding and appreciation for Teva’s culture of innovation and our outstanding people. As we continue to focus on integrating and realizing the value of the Actavis Generics transaction, which is progressing according to plan, Dipankar and his team will focus on generating organic growth through new launches and replenishing the pipeline through our industry-leading R&D, and drive efficiencies across the generics organisation,” said Erez Vigodman, president and chief executive officer, Teva.